Literature DB >> 28628227

MicroRNA-mediated drug resistance in ovarian cancer.

Aynaz Mihanfar1,2, Amir Fattahi3,4, Hamid Reza Nejabati1.   

Abstract

The development of intrinsic or acquired resistance to chemotherapeutic agents used in the treatment of various human cancers is a major obstacle for the successful abolishment of cancer. The accumulated efforts in the understanding the exact mechanisms of development of multidrug resistance (MDR) have led to the introduction of several unique and common mechanisms. Recent studies demonstrate the regulatory role of small noncoding RNA or miRNA in the several parts of cancer biology. Practically all aspects of cell physiology under normal and disease conditions are reported to be controlled by miRNAs. In this review, we discuss how the miRNA profile is changed upon MDR development and the pivotal regulatory role played by miRNAs in overcoming resistance to chemotherapeutic agents. It is hoped that further studies will support the use of these differentially expressed miRNAs as prognostic and predictive markers, as well as novel therapeutic targets to overcome resistance in ovarian cancer.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemotherapeutic agents; miRNAs; multidrug resistance; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 28628227     DOI: 10.1002/jcp.26060

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  27 in total

1.  HOXA11-AS induces cisplatin resistance by modulating the microRNA-98/PBX3 axis in nasopharyngeal carcinoma.

Authors:  Haineng Li; Jia Huang; Sa Yu; Hangbo Li; Yan Zhou; Qingwei Wu
Journal:  Oncol Lett       Date:  2021-04-26       Impact factor: 2.967

Review 2.  Exosomal miRNAs in osteoarthritis.

Authors:  Aynaz Mihanfar; Seyed Kazem Shakouri; Mohammad Hassan Khadem-Ansari; Amir Fattahi; Zeinab Latifi; Hamid Reza Nejabati; Mohammad Nouri
Journal:  Mol Biol Rep       Date:  2020-04-10       Impact factor: 2.742

3.  Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.

Authors:  Kira Philipsen Prahm; Claus Høgdall; Mona Aarenstrup Karlsen; Ib Jarle Christensen; Guy Wayne Novotny; Estrid Høgdall
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

4.  A Novel Mechanism of Doxorubicin Resistance and Tumorigenesis Mediated by MicroRNA-501-5p-Suppressed BLID.

Authors:  Yun-Chao Xu; Xu Liu; Min Li; Yan Li; Chun-Yan Li; Ying Lu; Jaceline Sanches; Lu Wang; Yue Du; Li-Min Mao; Si-Bo Zuo; Hui-Ting Liu; Jie Shen; Bo Wang; Li Hou; Lian-Hong Li; Jian-Wu Tang; Jing-Fang Ju; Hong-Wei Guan; Bo Song
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-05       Impact factor: 8.886

5.  Naringin inhibits ovarian tumor growth by promoting apoptosis: An in vivo study.

Authors:  Liping Cai; Heli Wu; Chunhua Tu; Xiaochun Wen; Bei Zhou
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

6.  MicroRNA-937 inhibits the malignant phenotypes of breast cancer by directly targeting and downregulating forkhead box Q1.

Authors:  Xiaoting Han; Xiaolong Guo; Wenzhen Zhang; Qiumei Cong
Journal:  Onco Targets Ther       Date:  2019-06-20       Impact factor: 4.147

7.  Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma.

Authors:  Steven F Chen; Zheng Liu; Shyambabu Chaurasiya; Thanh H Dellinger; Jianming Lu; Xiwei Wu; Hanjun Qin; Jinhui Wang; Yuman Fong; Yate-Ching Yuan
Journal:  Oncotarget       Date:  2018-04-17

8.  MicroRNA-101-3p inhibits proliferation in retinoblastoma cells by targeting EZH2 and HDAC9.

Authors:  Qifang Jin; Wenfeng He; Leifeng Chen; Yang Yang; Ke Shi; Zhipeng You
Journal:  Exp Ther Med       Date:  2018-07-04       Impact factor: 2.447

Review 9.  Non-coding RNA in drug resistance of hepatocellular carcinoma.

Authors:  Bisha Ding; Weiyang Lou; Liang Xu; Weimin Fan
Journal:  Biosci Rep       Date:  2018-10-09       Impact factor: 3.840

10.  FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer.

Authors:  Hui-Wen Chiu; Jeng-Shou Chang; Hui-Yu Lin; Hsun-Hua Lee; Chia-Hao Kuei; Che-Hsuan Lin; Huei-Mei Huang; Yuan-Feng Lin
Journal:  J Clin Med       Date:  2018-10-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.